Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
“Het voornaamste doel bij post-COVID is symptoomverlichting, vaak niet-medicamenteus”
jun 2026 | Virale infecties